Specialty medical injectable drug program, requirements and drug policy updates: Cimerli™ and Skyrizi®
New specialty medical injectable updates and requirements announced.
Sept. 22, 2022
- All states
- Operations
Please review the following table to determine changes to our specialty medical injectable drug programs.
Specialty medical injectable drugs added to review at launch
| Drug Name | UnitedHealthcare Commercial | Treatment Uses |
|---|---|---|
| Cimerli™ (ranibizumab-eqrn) |
X | Indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularization. |
Review the UnitedHealthcare Commercial Plan Review at Launch Medication List.
Updates to drug program requirements and drug policies for UnitedHealthcare commercial business effective Nov. 1, 2022
| Drug Name | Treatment Uses | Summary of Changes |
|---|---|---|
| Skyrizi® – IV formulation (risankizumab-rzaa) |
Used to treat adults with moderate to severe Crohn’s disease. | Add notification/prior authorization and Site of Care. Note: Subcutaneous self-administered Skyrizi is covered under the pharmacy benefit. |
For questions, please contact your broker or UnitedHealthcare representative.
More updates for your clients
New releases, updates and notifications for a broad spectrum of UnitedHealthcare products and services.
Important, required notices for products, plans, forms and more.
Need-to-know operational announcements for you and your clients.